Market Insights Health Pharmaceuticals Vaccines

Other Vaccines - Sweden

Sweden

The revenue in the Other Vaccines market in Sweden is projected to reach US$214.50m in 2024.
It is expected to show an annual growth rate (CAGR 2024-2028) of 9.36%, resulting in a market volume of US$306.80m by 2028.
In global comparison, United States is expected to generate the most revenue with US$23,850.00m in 2024.
Sweden is seeing a growing demand for other vaccines, as the government emphasizes the importance of preventive healthcare.

Key regions: United Kingdom, China, Europe, India, France

Market

Region

Region comparison

Currency

Analyst Opinion

The Other Vaccines market in Sweden has seen significant growth in recent years.

Customer preferences: Swedish customers are increasingly interested in preventative healthcare, leading to a rise in demand for vaccines. Additionally, the COVID-19 pandemic has heightened awareness around the importance of vaccines, leading to an increased interest in all types of vaccines.

Trends in the market: The Other Vaccines market in Sweden is characterized by a growing demand for travel vaccines, as well as vaccines for infectious diseases such as hepatitis A and B. There is also an increasing demand for vaccines for HPV and meningococcal disease. The market is expected to continue growing in the coming years as the Swedish government expands its vaccination programs.

Local special circumstances: Sweden has a well-developed healthcare system, with a high level of government involvement in healthcare provision. This has led to a strong public health focus, with a high level of vaccine coverage across the population. Additionally, Sweden has a high level of international travel, leading to a higher demand for travel vaccines.

Underlying macroeconomic factors: Sweden has a strong economy with a high level of disposable income, leading to a willingness to invest in preventative healthcare measures such as vaccines. Additionally, the country has a well-educated population with a high level of health literacy, leading to a greater understanding of the benefits of vaccines. The Swedish government also has a strong commitment to public health, with a focus on preventative measures such as vaccination programs.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.